Mydecine Innovations Group Inc (OTC:MYCOF, NEO:MYCO) (OTCMKTS:MYCOF) (NEO:MYCO) Chief Science Office Robert Roscow tells Proactive it has reported positive pre-clinical data for its drug MYCO-003 as a treatment for anxiety and post-traumatic stress disorder (PTSD) and updated on the candidate's patent progress.
Colorado-headquartered Mydecine also said it had now filed its final patent application for the drug with the United States Patent and Trademark Office (USPTO) and the World Intellectual Property Organization (WIPO).
What's more, Roscow says it plans to supply its lead drug candidate, MYCO-001, for a multi-site smoking cessation study being conducted at Johns Hopkins University (JHU), New York University (NYU), and the University of Alabama Birmingham by top drug and substance use researcher Dr. Matthew Johnson.